A New Look at Genetics Using Old Data: Alzheimer's Progression

Identifying new potential treatments for Alzheimer’s disease by understanding how the disease progresses.

We have spent billions of dollars and decades studying Alzheimer’s disease (AD), but have not yet found an effective treatment. Most are based on our research into understanding factors increasing the risk of getting AD. Modification of those factors is then used to see if the speed at which AD progresses can be slowed down. However, there is no evidence that the factors that determine the risk of getting AD are the same as those that affect the progression of AD. Genetics can tell us about biology. By reusing clinical trial data and their genetics, we can see what the biology of progression is.

We challenge the common assumption that the genetic factors increasing the risk of getting Alzheimer’s are the same ones that control how fast the disease worsens; we believe these might be different. We are “recycling” valuable data from the placebo groups of past clinical trials and bringing together multiple pharmaceutical companies and academic sources. This sounds like it should be common sense, but surprisingly, it is rare and not without its challenges.

For the general public, this research could lead to genetic tools that help predict an individual’s rate of decline, allowing for more informed care choices and future planning. For the research field, initially, it will enable the design of smarter clinical trials by grouping patients based on their genetic makeup related to disease advancement. Understanding the specific biology of Alzheimer’s progression will also reveal new, more effective drug targets.